


FIGURE 1

FIGURE 1



New US Com App of Dr ALMARRISON et al
1 of 13
COMPRISING TINNEM ANY DR # 10436-076-999, TD# 303-496-4400
FIELD 11/18/2022 FOR TOPICALS SALTS AND COMPOSITIONS
New US Com App of Dr ALMARRISON et al




FIGURE 2




FIGURE 3






FIGURE 4

FIGURE 5



new US Coop APP of ALMARISSON et al.
FIELD 11/18/02 Fcc; TOTIPERMALTE SALTS AND COMPOSITIONS
COMPRISING THEM ALY D1 # 1033-076-999; TGL 202-496
5 of 13

FIGURE 6



Dissolution curves of topiramate forms in 0.01 N HCl at room temperature.
The earliest timepoint is 4 minutes. All samples were continuously stirred using a magnetic disk.




FIGURE 7

FIGURE 8





FIGURE 9



Pharmacokinetics in rats after 30 mg/kg doses of the topiramate crystal form used in the marketed formulations and the highly soluble sodium salt. Samples (1)-(3) were placed in size 9 gelatin capsules (Torpac).




FIGURE 10




FIGURE II




FIGURE 12

12013
COMPRISING THEM ANY OR ALL OF THESE
FIBER TOPPLAMATE GELS AND COMPOSITIONS
New US Pat App of Olof ALMARISSON et al.




FIGURE 13